Investopedia: Synovis Has To Bow Out To Get Some Love

Biomaterials and medical tools company Synovis (Nasdaq:SYNO) has almost always been a source of frustration to me as a med-tech analyst. The company's products offer legitimate benefits and improvements over the state of the art, the company generated positive cash flow and management seemed no worse than competent and realistic.

And yet, this company just never got much love or attention. The trading volume was too low to attract sell-side analysts and the company too small to appeal to very many institutional investors. As a result, it takes a buyout by large-cap med-tech titan Baxter (NYSE:BAX) for the company to finally deliver some of its promise to its shareholders.

Read more here:
http://stocks.investopedia.com/stock-analysis/2011/Synovis-Has-To-Bow-Out-To-Get-Some-Love-BAX-SYNO-JNJ-BCR1215.aspx